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Violacein-producing bacteria, with their striking purple hues, have undoubtedly piqued the curiosity of scientists since their first
discovery. The bisindole violacein is formed by the condensation of two tryptophan molecules through the action of five proteins.
The genes required for its production, vioABCDE, and the regulatory mechanisms employed have been studied within a small
number of violacein-producing strains. As a compound, violacein is known to have diverse biological activities, including being
an anticancer agent and being an antibiotic against Staphylococcus aureus and other Gram-positive pathogens. Identifying the
biological roles of this pigmented molecule is of particular interest, and understanding violacein’s function and mechanism of
action has relevance to those unmasking any of its commercial or therapeutic benefits. Unfortunately, the production of violacein
and its related derivatives is not easy and so various groups are also seeking to improve the fermentative yields of violacein through
genetic engineering and synthetic biology. This review discusses the recent trends in the research and production of violacein by
both natural and genetically modified bacterial strains.
1. Natural Violacein-Producing Strains and
Their Locales Are Quite Diverse
As a bisindole, violacein (Figure 1) is produced by diverse gen-
era of bacterial strains, including Collimonas [1], Duganella
[2], Janthinobacterium [3–5],Microbulbifer sp. [6], and Pseu-
doalteromonas [7–9]. These violacein producers are varied
phylogenetically and so are the locales from which they
have been isolated. As shown in Table 1, these include quite
a selection of environs as these bacteria have been found
associated with the surfaces of sea sponges [7] and the
rhizosphere of olive groves [10] and even within glaciers
[4, 11, 12]. Perhaps the best known genus, however, is Chro-
mobacterium [13, 14], which includes the strain C. violaceum
[15].
2. Violacein as an Indicator of
Quorum Sensing
In most of violacein-producing bacterial strains isolated
from nature, this bisindole is a secondary metabolite that
is associated with biofilm production [5]. Moreover, its
production withinC. violaceum and other strains is regulated
by quorum sensing mechanisms [16]. Because it is easy to
visualize, violacein production by C. violaceum has become
a useful indicator of quorum sensing molecules and their
inhibitors [17–20].
Secondary metabolites often serve functions other than
the bacteria’s immediate needs in growth and propagation.
Many of these molecules are biologically active, and some
have toxic properties to competing species giving the bacteria
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Table 1: Some violacein-producing strains and the locales from
which they were isolated.
Strain Locale Reference
Chromobacterium violaceum
River
Waste water
treatment plant
[14]
[21]
Collimonas sp. Arctic coastalwaters [1]
Duganella sp. Agricultural soils(olive) [10]
D. violaceinigra Forest soils [22]
Janthinobacterium lividum Glacier [4]
J. svalbardensis Glacier [11]
Pseudoalteromonas sp. Deep sea waters(320m) [23]
P. luteoviolacea Sea sponge surface [7]
a competitive advantage. Because of these activities, many
secondary metabolites have been found to have pharmaco-
logical properties and, thus, are of interest for clinical use. In
the first half of this review, therefore, we will review some
of the biological functions, clinical significance, and mech-
anisms of action of violacein.
3. Violacein’s Function in
Nature-Predator Defense?
As noted above, violacein-producing bacteria encompass
various genera and are found in all types of natural envi-
ronments, from marine to freshwater and soil environments
(Table 1). For this reason, it is rather difficult to pinpoint
violacein’s main biological or ecological role. One possible
commonality is that violacein producers are generally sessile
bacteria whichmakes themmore vulnerable to predation [6].
This leads to the idea that violacein serves as some sort of
defensemechanism for its producing strain or that it provides
these sessile bacteria some competitive advantage.
Consistentwith this, violaceinwas shown to have antibac-
terial properties particularly towards Gram-positive bacterial
strains [36, 37]. One strain in particular that has received
most of the recent attention is Staphylococcus aureus, in part
due to its status as a multidrug resistant pathogen [37–40].
Two studies showed that crude violacein was capable of
inhibiting S. aureus growth at concentrations between 5.7 and
15mg/L, or approximately 17 to 43 𝜇mol/L [38, 40].
Violacein’s biological activity is not limited to prokary-
otes, however, as it is also known to have negative effects on
bacteriovorus protozoans and metazoans (Table 2). Matz et
al. tested purified violacein and violacein-producing biofilms
with various protozoan species that include flagellates, cili-
ates, and amoeba [6].They showed that, when exposed to vio-
lacein, the bacteriovorus amoeba Acanthamoeba castellanii
displays decreased feeding accompanied by morphological
changes, such as cell rounding. Further observations, such as
increases in caspase-3-like activity and TUNEL assay studies,
suggest that these predacious microbes are dying via an
apoptotic-like cell death [41].
Like many protists, the soil nematode C. elegans is a
bacteriovorus predator that ingests a wide variety of microor-
ganisms [42]. Although C. elegans is best known as a premier
genetic model organism that has propelled such important
discoveries as RNAi,microRNAs, and programmed cell death
[43–45], it is also an excellent tool to understand violacein’s
biological activity on bacterial predators. For example, C.
elegans fed E. coli as a prey strain grows normally and
healthily in the laboratory. However, two strains of bacteria
that produce violacein, Janthinobacterium sp. HH01 and C.
violaceum, were shown to be toxic to C. elegans [27, 46].
In particular HH01 exposures resulted in developmental
problems in juvenileworms, aswell as behavioral changes and
a rapid mortality in adult worms. Interestingly, an exposure
to a mutant HH01 strain that lacks violacein and tryptophan
production did not induce severe toxic effects, indicating
that the responses originated with the bisindole. As further
confirmation of this, E. coli carrying HH01 vioA-E genes
that produce violacein resulted in accelerated death, albeit at
a slower rate than in HH01. These experiments affirm that
violacein is likely toxic to the bacterial predator C. elegans.
In addition to its apparent roles in protecting the
bacterium from predation, violacein seems to have other
ecological functions that may provide advantages for the
bacteria that produce it. For instance, violacein-producing
Janthinobacterium forms biofilms and resides on the skins
of frogs and salamanders [24, 47]. In return, the violacein
produced provides antifungal protection for its amphibian
hosts, increasing their survival.
4. Potential Clinical Uses of Violacein
These functional studies portray the secondary metabolite
violacein as a toxic sentinel guarding against diverse potential
bacterial predators and other competitors. However, such a
broad cellular toxicity may also prove to be useful as a ther-
apeutic against various pathogenic and endogenous cellular
insults. Consistent with this, many pharmacological proper-
ties have been attributed to violacein.
Violacein has strong antibacterial effects making it a
promising candidate as an antibiotic.Moreover, when admin-
istered in combination with other antibiotics, the impact is
more effective in fighting bacteria than the use of antibiotics
alone [48]. This is of particular interest in light of recent
antibiotic-resistant strains of pathogenic bacteria, such as
MRSA. Also, the antiprotozoan properties of violacein could
be exploited to treat diseases in humans, such as in malaria
and leishmaniasis [25, 26].
The most studied clinical use of violacein, however, is
it being a potential cancer therapeutic. Violacein has been
tested against various cancer cell lines (Table 3), where it has
shown cytotoxicity at IC50 values that mostly range in the
submicromolar concentrations. The effects of violacein were
also shown to be specific for the cancer cell line tested as two
colorectal cancer cell lines, Caco-2 and HT-29, were differ-
entially susceptible to violacein [31]. Since violacein is cyto-
toxic towards noncancer cells as well [28, 34], the critical
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Table 2: Eukaryotic organisms in which violacein was shown to produce negative effects.
Type Organism Description Reference
Fungi Batrachochytrium dendrobatidis Infects amphibians [24]
Protozoa
Rhynchomonas nasuta Flagellate [6]
Tetrahymena sp. Ciliate [6]
Acanthamoeba castellanii Amoeba [6]
Leishmania amazonensis Causative agent of leishmaniasis [25]
Plasmodium falciparum Causative agent of malaria in humans [26]
Plasmodium chabaudi chabaudi Causative agent of malaria in mice [26]
Nematode Caenorhabditis elegans [27]
Table 3: List of cell lines tested against violacein.
Cell line Cell type Organism Notes Reference
V79 Fibroblast-like cell line from lung tissue Chinese Hamster [28]
FRhK-4 Fetal kidney Monkey [29]
Vero Kidney Monkey [29]
MA104 Kidney epithelial cells Monkey [29]
Hep2 Hela-derived Human [29]
92.1 Uveal melanoma Human [30]
OCM-1 Choroidal melanoma Human [30]
NCI-H460 Non-small-cell lung cancer Human [28]
KM12 Colon cancer Human [28]
Caco-2 Heterogeneous epithelial colorectal adenocarcinoma Human [31, 32]
HT29 Colorectal adenocarcinoma Human [31]
HCT116 Colorectal adenocarcinoma Human [32]
SW480 Colorectal adenocarcinoma Human [32]
DLD1 Colorectal adenocarcinoma Human [32]
TF1 Erythroleukemia Human [33]
K562 Lymphoma Human N/Ca [34]
U937 Chronic myelogenic leukemia Human N/Ca [34]
HL60 Promyelocytic leukemia Human [34]
MOLT-4 Acute lymphoblastic leukemia Human [28]
EAT Ehrlich ascites tumor Mouse In vivob [35]
aNo cytotoxicity observed.
bBoth in vitro and in vivo tests were performed.
factor for its clinical use against cancer is that it is more toxic
to cancer cells than to normal cells. One study demonstrated
that violacein induced apoptosis in HL60 cells (IC50 =
700 nM), a cancer cell line used as a model to study myeloid
leukemia. However, normal lymphocytes were unaffected at
the concentrations tested, further asserting violacein’s use as
a putative cancer therapeutic [34].
Violacein clearly has toxic effects on cultured cancer
cells, that is, within in vitro tests. Its ability to attenuate
cancer growth in vivo was also tested recently in the Ehrlich
ascites tumor (EAT) mouse model [35]. Daily intraperitoneal
injections of 0.1 𝜇g/kg violacein significantly increased the
survival rate of the mice, while no adverse effects were
observed in mice receiving higher doses of up to 1mg/kg.
5. Biological Mechanism of Violacein’s Effects
Even though violacein is a promising agent as an antibiotic
and a treatment for cancer, the biologicalmechanisms behind
these actions remain elusive. Before we can stamp violacein
as a natural therapeutic for numerous kinds of diseases, it
is imperative to understand its mechanisms of action at the
cellular and molecular levels.
Several groups have begun this and many of the studies
performed in cancer cell lines report increased activity in
indicators of apoptosis-related markers, such as increases
in the reactive oxygen species (ROS) and the activation of
caspases [31, 32, 34, 35]. However not all cancer cell lines
respond to violacein and the reason for the selectivity is not
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well understood. Moreover, among the leukemia cell lines
tested in the literature, violacein showed selective cytotoxicity
against HL60 and TF1 (Table 3), but the pathways that lead to
cell death were very different in the two cells. In HL60 cells,
an exposure to violacein led to phosphorylation of p38 MAP
kinase, upregulation of the NF𝜅B pathway, and activation of
caspases [34]. It was also found that TGF𝛼 receptor activation
was required for these downstream effects. TF1 cells, on the
other hand, did not seem to follow the canonical apoptotic
pathway as treatmentwith inhibitors of proapoptotic caspases
did not prevent cell death [33].
Conclusions on violacein’s mechanism of action are
clearly scant at this point. However, the fact that violacein
has cytotoxic effects on such a wide variety of organisms and
cells hints at a common target or pathway. Studying the effect
of these bisindoles at the genetic level on model eukaryotic
organisms, such as C. elegans, will help in elucidating its
mechanism of action and enrich our knowledge of violacein
as a clinical therapeutic. Owing to its versatile activity against
many human ailments and infectious agents, however, it is
not surprising that this bisindole has garneredmore attention
recently from the scientific community. One factor that may
contribute to reducing violacein’s application, though, is its
relatively low level production by natural strains. Conse-
quently, the latter half of this review will be primarily given
to the discussion of current research into the production and
purification of violacein and its related derivatives.
6. Production of Violacein by
Natural Host Strains
Since violacein is produced naturally by various bacterial
species, the use of these strains for its production seemed like
a clear choice. However,many factors were found to influence
the yields, including the agitation and aeration [7], the inocu-
lum size [2, 10], and the nutrients available [2, 10, 49, 50]. It
should be noted that the violacein concentrations reported
within many of the articles are based upon the extinction
coefficient as determined by the authors using spectropho-
tometric analyses, with extinction coefficient values ranging
between 10.955 and 74.3 L/(g-cm) in the literature [2, 49,
51, 52]. A recent article by Rodrigues et al. highlighted the
discrepancy caused by spectrophotometric-based determi-
nations of violacein and deoxyviolacein concentrations and
stated that this could result in violacein concentrations that
are inflated by as much as 680% [51]. To address this in their
study, therefore, Rettori and Dura´n (1998) relied on HPLC
measurements, a technique which was proposed in an earlier
study to be used in parallel with NMR, UV-Vis spectroscopy,
and mass spectroscopy when characterizing violacein and its
production by bacterial strains [52]. Consequently, to avoid
any potential confusion to the readers, this report will provide
the violacein and deoxyviolacein concentrations reported
and state whether they were determined via HPLC or with
an extinction coefficient.
One group applied response surface methodologies
(RSM) to identify the best conditions to produce violacein
with C. violaceum [49]. They initially analyzed 16 variables
but eventually limited them to three—glucose, tryptone, and
yeast extract. While the latter two improved both the cell
mass and violacein yields as they were increased, glucose was
found to be negatively correlated with the violacein yields,
and limiting its addition to the culture was advantageous.
Using this technique, they were able to increase the dry cell
weight (DCW) from7.5 to 21 g/L and the violacein yields from
170 to 430mg/L with an extinction coefficient of 56.01 L/(g-
cm). Although there was a significant improvement in the
volumetric productivity of violacein, defined as the mg of
product per liter of culture, it should be noted that this does
not represent a greater specific productivity of this bisindole,
that is,mg product per gramof cells, as the cellmass increased
by 2.8-fold while the violacein concentration increased by
only 2.5-fold. Yet, similar protocols could potentially be
employed with other strains to increase the cell density and,
thus, raise the volumetric productivity.
A more recent study using RSM with another violacein-
producing strain, Pseudoduganella sp. B2, previously
Duganella sp. B2, found similar results as the concentration
of beef extract usedwas amajor impetus for violacein produc-
tion [2]. They also identified the culture pH and the concen-
trations of tryptophan and potassium nitrate as major play-
ers influencing the final violacein yields. The importance
of tryptophan is not surprising as this is the precursor for
violacein,while the impact of nitratewas thought to be related
to nitrogen source availability for the growing bacterial
cultures. Under the optimal conditions found, the authors
claimed Duganella sp. B2 was capable of producing 1.6 g/L
crude violacein, typically referring to the naturally produced
mixture of violacein and deoxyviolacein. This value is under
scrutiny, however, as the extinction coefficient used (10.955 L/
(g-cm)) is the lowest reported in the literature [2, 49, 51, 52].
7. Production of Violacein within E. coli and
Other Heterologous Hosts
Since the genes required for the production of violacein are
known to exist within a single operon, that is, vioABCDE
[53], many groups have sought to clone and express these
within other bacterial hosts, including E. coli [8, 51, 53].
The Pemberton group has focused on plasmid stability, an
issue when trying to generate bacterial products in long term
and in nonnatural hosts. They found, for instance, when
the violacein gene cluster was cloned into pHC79, a cosmid
vector, that it was unstable and was lost in as much as 60%
of the bacterial population when grown for 15 generations in
the absence of antibiotic pressure [54]. They claimed that the
same was true when they expressed the vioABCDE operon in
a pUC18 vector but were able to generate a stable construct
using a broad host range IncP plasmid [54, 55].This plasmid,
pPSX-Vio+, was stable without antibiotics for more than 100
generations [54], making it a potentially useful tool for the
production of violacein.
In a subsequent study, they found that the amount of
violacein produced by E. coli was dependent upon the host,
with E. coli strain JM109 producing 3.9-fold more violacein
than E. coli strain DH5𝛼 when harboring the same plasmid
[55]. The production of the alpha amylase protein, AmyA,
from Streptomyces lividans was likewise found to be better in
BioMed Research International 5
NH
Violacein Deoxyviolacein Oxyviolacein
O
O
OH
OH
HO
HN
N
H
NH
NH
O
O
O
O
HN
HN
N
H N
H
Figure 1: Structures of violacein, deoxyviolacein, and oxyviolacein showing either the presence or the lack of the hydroxyl groups. The
structures were prepared using ChemDoodle 2D sketcher (http://web.chemdoodle.com/demos/sketcher).
JM109 than DH5𝛼, demonstrating that this phenotype was
characteristic of JM109 and not due to the violacein genes.
The authors attributed better results with JM109 to the genetic
differences between the host strains but did not delve deeper
into the mechanisms underlying this phenotype. However,
they did identify amutationwithin the plasmidwhich led to a
further enhancement in the violacein yields [55]. This muta-
tion, which the authors designated as opv-1 (overproduction
of violacein), results from the deletion of a single nucleotide
within the region upstream of the vioA gene, leading to a
4.2- and 2.9-fold enhanced violacein yield from E. coli strains
DH5𝛼 and JM109, respectively.
A more recent study sought to engineer E. coli and its
metabolic pathways to improve the violacein yields [51].
For this, the authors overexpressed the genes related to
tryptophan production and knocked out several genes and
pathways which would detract the carbon flux away from this
amino acid. The engineered E. coli strain, TRP11, produces
about 20𝜇mol tryptophan per gramDCW(gDCW). By com-
parison, the control wild-type strain only produced about
0.3 𝜇mol tryptophan/gDCW, representing an increase in the
tryptophan concentration of more the 60-fold. They next
introduced the vioD gene into the chromosome of this strain
and a plasmid expressing the vioABCE genes. Performing fed-
batch fermentations over a 12-day period with this strain,
which they designated as Vio-4, they were able to generate
710mg/L violacein at more than 99% purity, demonstrating
that E. coli can be used to produce high level concentrations
of this bisindole specifically. E. coli, however, has not been
the only strain to have been used as a host to produce the
bisindole violacein. Both Citrobacter freundii and Enterobac-
ter aerogenes have also been used with positive results [56].
8. Deoxyviolacein and Oxyviolacein
Although violacein has received most of the attention, it
is not the only compound being produced by the VioA,
VioB, VioC, VioD, and VioE proteins within these bacterial
hosts. A recent article that describes the various products
in detail was recently published and lists over a dozen
different compounds that have been produced in tests with
various strains, mutants, and cell-free extracts [13]. Perhaps
the best known derivative produced by the violacein biosyn-
thetic pathway, however, is deoxyviolacein. In J. lividum, for
example, deoxyviolacein (Figure 1) is also being produced,
albeit at a lower level than violacein [57]. Similar results were
also seen with Duganella sp. B2 where the production of
deoxyviolacein was lower than that of violacein, as measured
by HPLC [58]. The percent deoxyviolacein within the crude
violacein extracts obtained from the natural bacterial hosts
is typically around 10∼20%, with the vast majority being vio-
lacein. This is also true for commercially available violacein
from Sigma-Aldrich, which is prepared using J. lividum and
certified as at least 85% violacein based upon HPLC analysis.
Deoxyviolacein, which lacks a hydroxyl group (Figure
1), can be produced by omitting the VioD protein. Using a
recombinant Citrobacter freundii carrying a plasmid with a
knock-out in the vioD gene, a recent study by the Xing group
reported on the high level production and characteriza-
tion of deoxyviolacein [58], with an emphasis given to
the differences between violacein and deoxyviolacein. Their
study showed, for example, that the photostability of deoxyvi-
olacein was slightly better than violacein in tests with either
natural or UV light. Moreover, in 24-hour toxicity tests with
HepG2 cell lines, violacein and deoxyviolacein were both
found to be toxic. However, the impact of violacein was dose-
dependent as greater additions of this bisindole led to greater
concomitant losses in the HepG2 viability. In contrast, the
toxicity of deoxyviolacein was not dose-dependent but led to
fairly consistent and stable losses in the viability over a range
of concentrations (0.1–10𝜇M). The difference between these
two bisindoles was even more pronounced when the viability
was determined after 48 hours.
Several groups have also shown that the proteins respon-
sible for the biosynthesis of violacein are not strict for their
typical substrate, tryptophan, as 5-hydroxytryptophan can
also be used to produce another derivative, oxyviolacein
(Figure 1) [59, 60]. In contrast to deoxyviolacein which lacks
a hydroxyl group when compared with violacein, oxyviola-
cein boasts an additional hydroxyl group. Likewise, as the
loss of the hydroxyl group in deoxyviolacein reduced its
efficacy against S. aureus, the presence of this extra hydroxyl
group within oxyviolacein was found to increase the potency
against these human pathogens [61].
9. Conclusions
This review presents current research trends regarding the
study and production of the bacterially produced bisindole
violacein and several derivatives. As a secondary metabolite,
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violacein has been found to possess a wide variety of bio-
logical activities, including anticancerous properties. These
characteristics have led to renewed interest in this compound
and its production by both wild-type and recombinant
bacterial strains. As presented in this report, the production
and characterization of violacein are not without their own
obstacles and struggles, andmuchwork still needs to be done.
This is particularly true regarding the mode of activity of
violacein which needs to be studied more in depth. Current
trends in molecular genetics are aiding in this as research-
ers are now capable of engineering bacterial host that can
overproduce this bisindole within fermentations. As work
with this compound and its derivatives progresses, it is anti-
cipated that violacein will become more readily available for
the scientific community and clinical studies.
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